patients olanzapine incidence at least twice that for
play

- ,-- patients (olanzapine incidence at least twice that for - PowerPoint PPT Presentation

Jan 20, 2023 •247 likes •526 views

Dr. William Wirshing: State of Alaska's Expert "They are among the most powerful disease modifiers in all of medicine They are a godsend to most people:' Tr.170,Ln.15-21 pip:o~I).I\W_).b] ",_~ ""rirrlo_~.

  1. Dr. William Wirshing: State of Alaska's Expert • "They are among the most powerful disease modifiers in all of medicine •••• They are a godsend to most people:' Tr.170,Ln.15-21

  2. pip:o~I).I\W_).b] ",_~ ""rirrlo_~. (K,~IO,u<l, ~ .~ _ ~ (I._~U O~ "'~ ~~ 't~(_);"""!L 1996 Label- Zyprexa Prescribing Information =. <-, __ ... _....... ' . i' .. iol ='<I' • (~I -. l1oo~~ ('-"""TO" Th<_._I>C,,H .... .s. __ ... -..... _dl"' .... .. cf' ... -""""""" -_ .. ..-. ...... _ • Z'tJ'MX.< _ ... __ "" __ ooIl'. .. (><_, .. 'O .. (" _____ .. ' .""*C .... _ _ ... _ _ _ • or _- .... -.-. ..... - ... No. 2.u-. ~ lJG<»,)'lII'<WI_IljG .. """",1 ~ 1_ ... - ... _ _ , .... _, n _ _ ... _ _ .... """"_ ClJ"'C<L PlUIlMACOLOCY ",.. _ H, (K,ol oM, ."""Ii< ~I ___ ltrr.....,(k.04 ' I olסi._"1. IKo-II-" oM), oM)('f' ,I. __ .. ~~._~ __ _ .. ,. ~I~ _ LIlio:' nIol). _ .<lO<tiMotrl' _. ..... _ Tho ,t ,- .... _ ... _'"",(,..,.>l .nr. ..... .. _ _ ,.""'bo<ol""'l""'4 __ ... ,trr, • __ .o.;lo'o_oI .... _~ .. : ....... _d1-..-.~ d1_ ... __ ... ,. .. """"'d1_"'_"",«fOM'" 01_101 .. __ ,..- - '.....,., = ' ',... i' .. ., .......... -.", -.. .. _......,.61 .•• 1oIIow'ooo;_<nI-.. iI._ '*"'''''''lIrb""" _bolio ... __ ..... _ 0'''' ! .. ' El 2954

  3. -_._-~._._-_ 1996 Zyprexa Label: Weight Gain Information Adverse Reactions: Commonly Observed Adverse Events in Short-Term, Placebo-Controlled Trials- The most commonly observed adverse events associated with the use of olanzapine (incidence of 5% or greater) _, .. r_ .. __ ..... and not observed at an equivalent _ .. __ ..... _- , ._-_r -----_ .. _ .. 'm ,." incidence among placebo-treated __ n._ t - ,-- patients (olanzapine incidence at least twice that for placebo) were: -' -- - --- - - ••• " Weight gain: olanzapine = 6% placebo = 1 % • (emphasis ildded) , ........

  4. ~ 1996 Zyprexa Label: Weight Gain Information e=- >:'- Adverse Reactions: ••• """--- During long-term continuation therapy --_ "'-----_.- with olanzapine .. .56% of olanzapine ........... _-,,- "' ...... -"._ _ 1',""2 '"" .... _ ..... __ .. _"" ~ --'-"0 •• ..-_ ........ __ .. ,MI" patients met the criterion for having ----"',,---_ ..... ,,-- , . __ -_ .. ,--_ _- __ ,. __ IMl_._ .. __ ,_"_._ _,, .... __ (IWll_. gained greater than 7% of their baseline weight. . __ .. _-~-, --""'-'"----"'''--_ . Dno ... (nI_ ,,_ ...... ..... (emphasis added)

  5. '996 Zyprexa Label: Hyperglycemia and Diabetes Information Other Adverse Events Observed During the Premarkering Evaluation of Olanzapine • Frequent adverse events are those occurring in at least 1/100 patients (only those not already listed in the tabulated results from placebo-controlled trials appear in this listing) .... Infrequent adverse events are those occurring in 1/100 to 1/1000 patients ... Endocrine System -Infrequent: diabetes mellitus .. _ • • • Metabolic and Nutritional Disorders- ... Infrequent: ... hypergIycem ia ....

  6. ~ =~ ,~..., -~ '_"_"U_~""" ~·r. A,.~""."" ~~" ~"-., ,~..- --~ ~ _ - ' · I _.~~ ~"'._ ~,_ ~ ~ -~ ~-~ _~.I7l_ -~ ...._-~-<--_ c_~~ Medical Letter: Zyprexa - Body Weight Changes - ""'-'" _._ ... __ . __ .... - ~ . ""'X.I· __ IIOOY .. ,""" ,",_. ........ _ ..... ---..- .. - ------ .. - ..... .. _-_ .. "'---- '- ",-01,,,,_--<,. _ ... _~_, .. ., ... ~,,". ........ _ .. _ .............. _-""""'-.- ...... ")j_ ... - ..... ,." ... " , ............. ,-.-- .... __ .... - .. -- -_ ... _ ........ __ .- ... ...................................... ...... __ .............. ,'.--_.- .... --" .. " .. _,,, ... -...~ _ ..... _>1 _ .. _ .... _ ,_"",...-, • ..,_ --'--"--'--'_._" .. _ .. , .......... ..--.._-- ....... _'-" , .. _- _ ......... AI'<l~ ..... ""' .... _ ... ~_~.-lJ.>J ---_ ..... _ ..... --_ .. -- .... - .... __ .- ... _._---' .......... ..... ..- .................... - ,- w ...... __ .. ____ "" .... ",,;; ........ , ... ,..--._.,,",- .. ---_ . ... ---- -----.- .... _ _" .... ,._"' .. _ . ...... -- ...... --.- .. -_ ... ',,' ... - ........ ---' .... , ..... ,,- -_.- -" ...... _-~ ..... ,,-- ... _._"_.- _ .... , ..... ,_ ....... _ ........ -. ... ~ .... r...... -""'~ ......... _._~ ... -,-- .... _,_ n. •...,. ....... ___ •• """"-""'" -_ ... ,. •• ~,.<.\ ... .' • - .. -.~- "-_ .. -.--.""'---""'-t.:: ... ...-",,, ...... - ..... , ... " '" ~'-"'; !' // ,_.,. ..... ",""""' ... __ .. '" ........ ""' .... _,"""' .... ,"' .... , ... ""'f* __ _. __ .... , ....... _ ... , ,------_ .. ,..-- .............. -_ ... - ""---_.,,,,,--_ .... ... - ....... _, ..... ' -"'E':~ 00.,,,, . ...,.--"...."' ... _._ ........ , I : 1."'-' ,,.,,,, "."'" ~...,.., ,_ •• ~ J _ .. _ ... .--, .. _ ... _. ,,,_ . , - .. -- ,---_ ... ~--- - ..... __ .~ ........ I . " ... --_ ... _--_ .. _ , _ "". - ... ----, ... "._ ........ ,";",.; •• __ .. _" '''''"' .. .... ..- .... 11"] .. "-"'-~'l. "."",----,--..., .. """_'",,,' ._ ...... _ .. - . . . - ... --_." ........... _~ ... _-'"" .... _, ... _ .. ~~ -_._.-._ .... ~.,_ ... _-,~-'." ...... _._ .. - ........ - ... ... __ __ ... " ,-~- ..... _~ .......... _~-,~ .. _ - _. , ... _-- ....... _._-_.,""" ....... ., ....... ....,-'"*', ..... ~-- .... -" "'---,,' ... ,-. .. -..,_ .. ' ... ----,_ .. -... .. ,-_ .. "_I_"-"'''l·'''J, ... "",_~_r ..... _- ........... _ _""0 .. _._-.- ......... -<, ... ,-..._-" .. _ ,--.,,-,< ... ~--- , ........ __ .... ... ~- __ '''''''' .. - ....... - .... ---~"'_._ -. _. ",-_-, ... ____ ...... ... _--_ .... --.-. .. _ .... _._ "_-_"1"'-- __ " "" ...... " ~ ...... c •• _",,,.,,,,,,,-. .. _ • , , ' ......... _~ ..... ____ ... .... ~_."" ..... " ..... _'_'j -"'---"- ..... - .... - .... "''''''''OJ. __ '''''' ." ... "" .. _~_ ..... _--._, ... - ...... ,,,., . _ , ........... _--~_ ......... "'. __ ... ~ ........ ---~--'-~--_. -_ ... ~ .... _._.,- .... wl ...... ,,_._,.,. __ ........... _._ ....... _ ..... ....... ...- Of ____ .... ~ .. -- ....... _ ..... _ .... <".,--- ...... EL 2991

  7. -_.,-~_. -""-~ ~----,-_. ,,~,..'~,,_'-._ ,w~" ~- Medical Letter: Zyprexa - Blood Glucose Changes .. _-_._-_ ... - "'-, ..... _,.-......,-,.,_-.. ,- , --------_ .. .. """" ......... _._--- .. "'''''''''''' o<M,.. .. ... _ - _ - .. _--""- '''''''''''''.-'-<LU:<lSlC>lAl'Gn ..,,,...- .. -- ... - ,- '''' ... __ ,..- ...... .. I _ _-,._ .. _._-_ .. - --'''' --; -." '-"- ... -_ """"' -- .... _,,--_. ---_ ... _---- .. _---_._ ... -- -_-.._ ...... _.- --, -----_ ... _.~ ..... ~ ... -<-I .. _-- """' ... _-_. ..... _ ---_._ .. _""'""'---- _.----_ .... --"..-- V .... ,. L __ _ ..... -_ .. _--_ ... _ .. _ ... .- -_ .. _._-_ .. _-- .- .... -._- ___ "_."' __ ",,_""'..-e_ ....... , '-' __ ,_ .. ""_ .. _ ---<.., ... __ ._---- ..._ .... --- .,., .... _-- ---..-.--_._-+ ' .. ... _ ... _~-... -_._ _..., ..... _~ ... _ _-, .. _---- 0. .... _---_ ..... _ .... ,-- -_ .. __ .... _-,,--- ---- .. -_ .. w. __ _ " -,,---- '"""''--- ._-, .. _ '_oNoo .. _----,-_ . __ .. _- .. '1 ......, •. ",,_ .... _ , .. _ .... "" , .. _ .... - .. _--_ ........ -.....-. ........ ,,,....,.0>11_,, __ \< ...... _ .... _- _ ... __ ._ ....... __ ..... _ .. _"'_ .... .. - .,,,".\ " ..... , ..... _ lJ ............ ". ..... _-_ .. .,.. .. --._- -'-""--=--"'-- _._ .. _ .. _ ''''-'1"'---'''''''' ........ _ .. __ ---- ... --- .. _---_._-_ ... .. _ .... • __ no __ • _ -_ .... _-_ --."- ................ - ... _ -------_ ..... ,-_ .. --,--- ,"" ... ' ... __ _-_ ... -_ .. .. ,------- -_ ....... _---'---- "'-_ .. _ .. "'---_ .. ,-_ .. _---,._,- "--"' ---_ .. -----_ .. _ .... ..-.- .. _ ----- .. .".,-- .... __ ... - .. _ ........ -, .. _--- "" ...... _ . ... ..-.....-_.,..1_ ... __ _ ,1< .. , .. """"- _ tv .." ,., '" .." ' .. EL 2986

Download Presentation
Download Policy: The content available on the website is offered to you 'AS IS' for your personal information and use only. It cannot be commercialized, licensed, or distributed on other websites without prior consent from the author. To download a presentation, simply click this link. If you encounter any difficulties during the download process, it's possible that the publisher has removed the file from their server.

Recommend

Changes in the Incidence of PML in Changes in the Incidence of PML in Tysabri- -treated

Changes in the Incidence of PML in Changes in the Incidence of PML in Tysabri- -treated

Changes in the Incidence of PML in Changes in the Incidence of PML in Tysabri- -treated Patients: treated Patients: Tysabri How best to communicate to patients How best to communicate to patients and physicians and physicians Division of

344 views • 13 slides
Increasing Incidence of Osteoporosis in Patients Prescribed Opioids After Having Various

Increasing Incidence of Osteoporosis in Patients Prescribed Opioids After Having Various

Increasing Incidence of Osteoporosis in Patients Prescribed Opioids After Having Various Orthopedic Surgery Procedures Rushabh M. Vakharia, M.D. Ajit M. Vakharia B.S., Tsun Yee Law M.D., M.B.A., Derek Berglund M.D., Jennifer Kurowicki M.D.,

164 views • 15 slides
The Incidence of and Risk Factors for Thromboembolism in

The Incidence of and Risk Factors for Thromboembolism in

The Incidence of and Risk Factors for Thromboembolism in Older Patients with Newly Diagnosed Multiple Myeloma Ang Li, MD, MS Acting Instructor Division of

848 views • 28 slides
1 However, Poorer survival for elderly campaigns have not reversed the early-life sun exposure

1 However, Poorer survival for elderly campaigns have not reversed the early-life sun exposure

Age distribution melanoma patients Epidemiology of melanoma in older patients Maryska Janssen-Heijnen Source: Eindhoven Cancer Registry Trends in age-specific incidence Elderly melanoma patients Literature: Elderly with melanoma compared to

564 views • 3 slides
Bucindolol is Associated with a Lower Incidence of Dose Limiting Bradycardia in Heart Failure

Bucindolol is Associated with a Lower Incidence of Dose Limiting Bradycardia in Heart Failure

Bucindolol is Associated with a Lower Incidence of Dose Limiting Bradycardia in Heart Failure Patients with Atrial Fibrillation: The GENETIC-AF Trial Abraham WT, Bristow MR, Piccini JP, Healey JS, van Veldhuisen DJ, Anand IS, White M, Wilton SB,

313 views • 12 slides
1 Tax Incidence: General Remarks Tax Incidence: General Remarks There are three basic rules for

1 Tax Incidence: General Remarks Tax Incidence: General Remarks There are three basic rules for

Introduction Lecture 10 Many policies center around whether the tax burden is distributed fairly. Not as simple as analyzing how much in taxes each person actually paid, because of tax induced changes to price. Tax Incidence 1 2 Tax

814 views • 7 slides
ACUTE KIDNEY INJURY Stuart Linas U. Colorado SOM Marked increases in incidence of

ACUTE KIDNEY INJURY Stuart Linas U. Colorado SOM Marked increases in incidence of

ACUTE KIDNEY INJURY Stuart Linas U. Colorado SOM Marked increases in incidence of dialysis-requiring AKI in last decade JASN 24 37 2013 Question 1 Of patients who recover from an episode of AKI, what percentage have CKD Stage 3-5 at 10

1.3k views • 116 slides
INCIDENCE OF Disease foodborne? Criteria: FOODBORNE DISEASES Food attribution

INCIDENCE OF Disease foodborne? Criteria: FOODBORNE DISEASES Food attribution

INCIDENCE OF Disease foodborne? Criteria: FOODBORNE DISEASES Food attribution Agent from patient(s) found in food (fingerprinting) Food consumption matches Dean O. Cliver among patients (help from Michele Jay-Russell)

381 views • 8 slides
Tax Incidence in sub-Saharan Africa Presentation for Taxation &amp; Developing Countries 16 Sept

Tax Incidence in sub-Saharan Africa Presentation for Taxation &amp; Developing Countries 16 Sept

Tax Incidence in sub-Saharan Africa Presentation for Taxation &amp; Developing Countries 16 Sept 2013 at ODI Oliver Morrissey CREDIT, School of Economics, University of Nottingham Network member of ICTD Tax Incidence Outline Incidence

473 views • 11 slides
Its Not A Tumor! n Increasing incidence of cancer Oncologic Emergencies n Improved survival n

Its Not A Tumor! n Increasing incidence of cancer Oncologic Emergencies n Improved survival n

Oncologic Emergencies Its Not A Tumor! n Increasing incidence of cancer Oncologic Emergencies n Improved survival n Patients with malignancies may present to Diane M. Birnbaumer, M.D., FACEP EDs and general medical offices Professor of

529 views • 13 slides
Its Not A Tumor! Increasing incidence of cancer Oncologic Emergencies Improved survival

Its Not A Tumor! Increasing incidence of cancer Oncologic Emergencies Improved survival

Oncologic Emergencies Its Not A Tumor! Increasing incidence of cancer Oncologic Emergencies Improved survival Patients with malignancies may present to Diane M. Birnbaumer, M.D., FACEP EDs and general medical offices Professor of

438 views • 17 slides
THE INCIDENCE AND COSTS OF THE INCIDENCE AND COSTS OF CHEMOTHERAPY SIDE EFFECTS CHEMOTHERAPY

THE INCIDENCE AND COSTS OF THE INCIDENCE AND COSTS OF CHEMOTHERAPY SIDE EFFECTS CHEMOTHERAPY

THE INCIDENCE AND COSTS OF THE INCIDENCE AND COSTS OF CHEMOTHERAPY SIDE EFFECTS CHEMOTHERAPY SIDE EFFECTS Alison Pearce - PhD candidate Centre for Health Economics Research and Evaluation, UTS Supervisors: Marion Haas, Rosalie Viney CAER 2013

414 views • 37 slides
My talk will focus on cancer incidence rates in Lambton County, incidence being the number of

My talk will focus on cancer incidence rates in Lambton County, incidence being the number of

My talk will focus on cancer incidence rates in Lambton County, incidence being the number of new cases of a disease diagnosed in a given population within a specified time frame. This analysis has been conducted as part of our public

492 views • 38 slides
5/22/19 Colorectal Cancer An Evidence Based Approach to Colorectal Lifetime incidence of 6%

5/22/19 Colorectal Cancer An Evidence Based Approach to Colorectal Lifetime incidence of 6%

5/22/19 Colorectal Cancer An Evidence Based Approach to Colorectal Lifetime incidence of 6% Cancer Screening Prevalence of 1% in asymptomatic patients aged 50-75 Common cause of cancer death, 2nd in men, 3rd in women Jay Ryan,

752 views • 10 slides
Recovery is in the eye of the beholder How visual fixation can predict TBI patients outcome

Recovery is in the eye of the beholder How visual fixation can predict TBI patients outcome

Recovery is in the eye of the beholder How visual fixation can predict TBI patients outcome Caroline Arbour, RN, PhD 12th annual conference, Brain Injury Canada September 30th, 2015 Annual incidence of TBI in Quebec About 400

454 views • 20 slides
Transplantation with post Transplant Cyclophosphamide for Patients Over 70 Years Samia Harbi, MD

Transplantation with post Transplant Cyclophosphamide for Patients Over 70 Years Samia Harbi, MD

Haploidentical Hematopoietic Stem Cell Transplantation with post Transplant Cyclophosphamide for Patients Over 70 Years Samia Harbi, MD 23/11/2018 - 18 e Congrs SFGM-TC-Nice Introduction : Haplo-SCT Low incidence of GVHD using PT-Cy

902 views • 19 slides
June 29th, 2018 1 Agenda Meeting goals and agenda overview Public comment (1:15 PM)

June 29th, 2018 1 Agenda Meeting goals and agenda overview Public comment (1:15 PM)

HEALTH ASPECTS OF KINDERGARTEN READINESS TECHNICAL WORKGROUP June 29th, 2018 1 Agenda Meeting goals and agenda overview Public comment (1:15 PM) Refresher on Phases 1-3 and measures Where weve been and where are we going

740 views • 32 slides
AHRQ National Web Conference on the Role of Telehealth to Increase Access to Care and Improve

AHRQ National Web Conference on the Role of Telehealth to Increase Access to Care and Improve

AHRQ National Web Conference on the Role of Telehealth to Increase Access to Care and Improve Healthcare Quality Presented by: Moderated by: Glen Xiong, MD Commander Derrick L. Wyatt Elizabeth D. Ferucci, MD, MPH Agency for Healthcare

1.03k views • 92 slides
Recovery LIVE! Changing the Conversation: Shared Decision-Making in Treatment and Recovery

Recovery LIVE! Changing the Conversation: Shared Decision-Making in Treatment and Recovery

Recovery LIVE! Changing the Conversation: Shared Decision-Making in Treatment and Recovery Support Services Settings Moderated by Devin Reaves, SAMHSA BRSS TACS Speakers: Valerie Gold Director of Training and Technical Assistance Programs, C4

690 views • 35 slides
Medicare Part C &amp; D Star Ratings: Update for 2017 August 3, 2016 Part C &amp; D User Group

Medicare Part C &amp; D Star Ratings: Update for 2017 August 3, 2016 Part C &amp; D User Group

Medicare Part C &amp; D Star Ratings: Update for 2017 August 3, 2016 Part C &amp; D User Group Call Session Overview Overview of Star Ratings Changes for 2017 Star Ratings and beyond HPMS Plan Preview and reminders Discussion:

659 views • 47 slides
Allergy and Immunology Pearls for Clinical Practice No discussion of non FDA approved

Allergy and Immunology Pearls for Clinical Practice No discussion of non FDA approved

Nothing to declare Allergy and Immunology Pearls for Clinical Practice No discussion of non FDA approved medication use Katherine Gundling, MD FACP Professor, Section Chief Allergy and Immunology UCSF Adverse Drug Reactions Adverse Drug

439 views • 11 slides
for the ABATE Infection Trial Team 1 Disclosures Participating hospitals in this trial

for the ABATE Infection Trial Team 1 Disclosures Participating hospitals in this trial

Susan Huang, MD MPH University of California Irvine School of Medicine Ed Septimus, MD Hospital Corporation of America for the ABATE Infection Trial Team 1 Disclosures Participating hospitals in this trial received contributed antiseptic

762 views • 50 slides
MOL2NET, 2017 , 3, doi:10.3390/mol2net-03-xxxx 2 was withdrawn, thereby forming a suspension, and

MOL2NET, 2017 , 3, doi:10.3390/mol2net-03-xxxx 2 was withdrawn, thereby forming a suspension, and

MOL2NET, 2017 , 3, doi:10.3390/mol2net-03-xxxx 1 MOL2NET, International Conference Series on Multidisciplinary Sciences MDPI http://sciforum.net/conference/mol2net-03 Antibacterial Potential Of The Alpha-pinene Positive Enantiomer Against The

486 views • 6 slides
Research Integrity Kevin T. Kavanagh, MD, MS Health Watch USA Nov. 4, 2016 This presentation is

Research Integrity Kevin T. Kavanagh, MD, MS Health Watch USA Nov. 4, 2016 This presentation is

Research Integrity Kevin T. Kavanagh, MD, MS Health Watch USA Nov. 4, 2016 This presentation is the explicit opinion of Kevin T. Kavanagh, MD, MS Research Integrity Dr. Richard Horton, the Editor of The Lancet, stated, The case against

787 views • 16 slides

More recommend